KRISTEN EUSEBE: Open Payments
NPI 1699550582 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,200 in 99 payments from 40 companies in 2025. Trend: 2023 $249 · 2024 $2,138 · 2025 $2,200
Food & beverage: $2,200
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $206 |
| Tempus AI, Inc | 5 | $165 |
| Janssen Biotech, Inc. | 9 | $162 |
| Novartis Pharmaceuticals Corporation | 8 | $156 |
| Astellas Pharma US Inc | 6 | $142 |
| Merck Sharp & Dohme LLC | 7 | $138 |
| Regeneron Healthcare Solutions, Inc. | 5 | $114 |
| PFIZER INC. | 3 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $83 |
| Eisai Inc. | 3 | $79 |
Products named: XT CDX, Enhertu, KEYTRUDA, Vyloy, Lenvima, KISQALI, LIBTAYO, IMFINZI.
Industry payments across TX — which companies pay providers there.
